GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation

Recognizing exceptional leadership in patient education and clinical skill in the GammaTile procedure 

TEMPE, Ariz., May 28, 2025 /PRNewswire/ -- GT Medical Technologies, a medical device company focused on improving the Saint Louis lives of patients with brain tumors, today announced SSM Health Saint Louis University Hospital as the latest GammaTile® Center of Excellence Program designation.

The program recognizes leaders in patient care dedicated to advancing brain tumor treatment. Physicians and their institutions who receive this designation have demonstrated an exceptional level of expertise in the GammaTile procedure by meeting specific clinical criteria, annual case minimums, and ongoing education requirements.   

The following physicians are now recognized with achievement:

• Philippe Mercier, MD, PhD, Associate Professor, Division Director, Neurosurgery
• Jeroen Coppens, MD, Professor, Neurosurgery
• Joanna Kemp, MD, Associate Professor, Neurosurgery
• Maheen Khan, MD, Assistant Professor, Neurosurgery
• John Dombrowski, MD, PhD, Associate Professor, Radiation Oncology
• Christen R. Elledge, MD, Assistant Professor, Radiation Oncology

"At SSM Health Saint Louis University we have developed a comprehensive neuro-oncology program with subspecialty trained neurosurgeons who incorporate the latest technology to improve the lives of our cancer patients," said Dr. Philippe Mercier, MD, PhD, associate professor and director of neuroscience at Saint Louis University, SLUCare and SSM Health Saint Louis University Hospital neurosurgeon. "GammaTile allows us to offer another option in the treatment of malignant brain tumors. We are also participating in multiple clinical trials which will help us further define the optimal use of GammaTile."

GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are most vulnerable. Unlike conventional approaches, which at their lowest often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.¹  

About GT Medical Technologies, Inc.
GT Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care.

About GammaTile
GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are most vulnerable to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue.

Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit gammatile.com and follow @GammaTile on Facebook, Instagram, LinkedIn and X. 

Media Contact
Dawn Fallon
New Dawn Communications LLC
[email protected]
732-771-7808

References

1. Garcia MA et al. J Neurooncol. 166:203-212 (2024).

SOURCE GT Medical Technologies